333 related articles for article (PubMed ID: 20206056)
1. [Endothelin receptor antagonists in the new European guidelines on pulmonary hypertension].
Montani D; Humbert M
Rev Mal Respir; 2010 Feb; 27(2):103-5. PubMed ID: 20206056
[No Abstract] [Full Text] [Related]
2. [Specific drugs for the treatment of pulmonary arterial hypertension - current status].
Stähler G
Dtsch Med Wochenschr; 2008 Oct; 133 Suppl 6():S183-6. PubMed ID: 18814092
[TBL] [Abstract][Full Text] [Related]
3. Ironic case of hepatic dysfunction following the global withdrawal of sitaxentan.
Don GW; Joseph F; Celermajer DS; Corte TJ
Intern Med J; 2012 Dec; 42(12):1351-4. PubMed ID: 23253000
[TBL] [Abstract][Full Text] [Related]
4. Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease.
Minniti CP; Machado RF; Coles WA; Sachdev V; Gladwin MT; Kato GJ
Br J Haematol; 2009 Dec; 147(5):737-43. PubMed ID: 19775299
[TBL] [Abstract][Full Text] [Related]
5. Oral Therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.
Lefebvre MC; Hunsche E
Appl Health Econ Health Policy; 2010; 8(1):69-71; author reply 71-3. PubMed ID: 20238466
[No Abstract] [Full Text] [Related]
6. [Guidelines for the diagnosis and treatment of pulmonary hypertension].
Sanchez O; Humbert M; Sitbon O; Jais X; Simonneau G
Rev Mal Respir; 2010 Feb; 27(2):141-50. PubMed ID: 20206062
[TBL] [Abstract][Full Text] [Related]
7. An evidence-based approach to the management of pulmonary arterial hypertension.
Coyne TC
Curr Opin Cardiol; 2006 Sep; 21(5):526; author reply 526-7. PubMed ID: 16900019
[No Abstract] [Full Text] [Related]
8. Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.
Langleben D
Clin Chest Med; 2007 Mar; 28(1):117-25, viii. PubMed ID: 17338931
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of pulmonary arterial hypertension: endothelin-receptor antagonists].
Hoeper MM
Dtsch Med Wochenschr; 2006 Dec; 131(49 Suppl 9):S308-10. PubMed ID: 17139593
[TBL] [Abstract][Full Text] [Related]
10. An evidence-based approach to the management of pulmonary arterial hypertension.
Archer SL; Michelakis ED
Curr Opin Cardiol; 2006 Jul; 21(4):385-92. PubMed ID: 16755209
[TBL] [Abstract][Full Text] [Related]
11. [The treatment of idiopathic pulmonary artery hypertension and its relation to systemic scleroderma].
Humbert M
Rev Med Interne; 2007 Dec; 28 Suppl 4():S273-6. PubMed ID: 17961866
[No Abstract] [Full Text] [Related]
12. Observational trials in pulmonary arterial hypertension: low scientific evidence but high clinical value.
Hoeper MM
Eur Respir J; 2007 Mar; 29(3):432-4. PubMed ID: 17329488
[No Abstract] [Full Text] [Related]
13. Endothelin antagonism in pulmonary arterial hypertension.
Lee SH; Channick RN
Semin Respir Crit Care Med; 2005 Aug; 26(4):402-8. PubMed ID: 16121317
[TBL] [Abstract][Full Text] [Related]
14. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
Chen YF; Jowett S; Barton P; Malottki K; Hyde C; Gibbs JS; Pepke-Zaba J; Fry-Smith A; Roberts J; Moore D
Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849
[TBL] [Abstract][Full Text] [Related]
15. Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension.
Beghetti M; Galiè N
J Am Coll Cardiol; 2009 Mar; 53(9):733-40. PubMed ID: 19245962
[TBL] [Abstract][Full Text] [Related]
16. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
Tapson VF; Torres F; Kermeen F; Keogh AM; Allen RP; Frantz RP; Badesch DB; Frost AE; Shapiro SM; Laliberte K; Sigman J; Arneson C; Galiè N
Chest; 2012 Dec; 142(6):1383-1390. PubMed ID: 22628490
[TBL] [Abstract][Full Text] [Related]
17. Transitioning between endothelin receptor blockers: monitoring to ensure a smooth transition.
Luo N; Ryan JJ
Can J Cardiol; 2013 Jun; 29(6):659-61. PubMed ID: 22985784
[No Abstract] [Full Text] [Related]
18. Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension.
Archer SL; Michelakis ED
N Engl J Med; 2009 Nov; 361(19):1864-71. PubMed ID: 19890129
[No Abstract] [Full Text] [Related]
19. [Hepatotoxicity in patients treated with endothelin receptor antagonists: systematic review and meta-analysis of randomized clinical trials].
Macías Saint-Gerons D; de la Fuente Honrubia C; Montero Corominas D; Catalá-López F
Med Clin (Barc); 2014 Apr; 142(8):333-42. PubMed ID: 23540381
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacological treatment of pulmonary hypertension at a turning point].
Watanabe H
Nihon Yakurigaku Zasshi; 2014 Apr; 143(4):165-72. PubMed ID: 24717603
[No Abstract] [Full Text] [Related]
[Next] [New Search]
